Acumen Pharmaceuticals, Inc.
Price
Overview
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
History & business model
This section is waiting to be written.
InvestWiki is community-edited. Contribute a plain-English history of Acumen Pharmaceuticals, Inc., its business model, key products, and controversies.